Increased rare duplication burden genomewide in patients with treatment-resistant schizophrenia

Psychological Medicine

Volumn 46, Issue 3, 2016, Pages 469-476

  Martin, A K ^a   Mowry, B ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

clozapine; copy number variants; Key words Age at onset; mutations; predictive models

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; AUSTRALIA; COHORT ANALYSIS; COPY NUMBER VARIATION; DRUG RESISTANCE; FEMALE; GENETICS; HOSPITALIZATION; HUMAN; MALE; MULTIFACTORIAL INHERITANCE; ONSET AGE; RISK FACTOR; SCHIZOPHRENIA; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; SUICIDE ATTEMPT; TREATMENT FAILURE; YOUNG ADULT;

ADOLESCENT; ADULT; AGE OF ONSET; ANTIPSYCHOTIC AGENTS; AUSTRALIA; CLOZAPINE; COHORT STUDIES; DNA COPY NUMBER VARIATIONS; DRUG RESISTANCE; FEMALE; HOSPITALIZATION; HUMANS; LOGISTIC MODELS; MALE; MULTIFACTORIAL INHERITANCE; RISK FACTORS; SCHIZOPHRENIA; SUICIDE, ATTEMPTED; TREATMENT FAILURE; YOUNG ADULT;

EID: 84965144486     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291715001701     Document Type: Article

References (47)

1. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. APA: Washington, DC.
2. Buizer-Voskamp JE, Muntjewerff JW, Strengman E, Sabatti C, Stefansson H, Vorstman JA, Ophoff RA (2011). Genome-wide analysis shows increased frequency of copy number variation deletions in Dutch schizophrenia patients. Biological Psychiatry 70, 655-662.
3. Cardno AG, Gottesman II (2000). Twin studies of schizophrenia: from bow-and-arrow concordances to Star Wars Mx and functional genomics. American Journal of Medical Genetics 97, 12-17.
4. ChakosM, Lieberman J, Hoffman E, Bradford D, Sheitman B (2001). Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: A review and meta-analysis of randomized trials. American Journal of Psychiatry 158, 518-526.
5. Crespo-Facorro B, de la Foz VO, Ayesa-Arriola R, Perez-Iglesias R, Mata I, Suarez-Pinilla P, Tabares-Seisdedos R, Vazquez-Barquero JL (2013). Prediction of acute clinical response following a first episode of non affective psychosis: results of a cohort of 375 patients from the Spanish PAFIP study. Progress in Neuro-Psychopharmacology and Biological Psychiatry 44, 162-167.
6. Dolzan V, Serretti A, Mandelli L, Koprivsek J, Kastelic M, Plesnicar BK (2008). Acute antipsychotic efficacy and side effects in schizophrenia: Association with serotonin transporter promoter genotypes. Progress in Neuro-Psychopharmacology and Biological Psychiatry 32, 1562-1566.
7. Fanous AH, Zhou B, Aggen SH, Bergen SE, Amdur RL, Duan J, Sanders AR, Shi J, Mowry BJ, Olincy A, Amin F, Cloninger CR, Silverman JM, Buccola NG, Byerley WF, Black DW, Freedman R, Dudbridge F, Holmans PA, Ripke S, Gejman PV, Kendler KS, Levinson DF (2012). Genome-wide association study of clinical dimensions of schizophrenia: polygenic effect on disorganized symptoms. American Journal of Psychiatry 169, 1309-1317.
8. Frank J, Lang M, Witt SH, Strohmaier J, Rujescu D, Cichon S, Degenhardt F, Nothen MM, Collier DA, Ripke S, Naber D, Rietschel M (2015). Identification of increased genetic risk scores for schizophrenia in treatment-resistant patients. Molecular Psychiatry 20, 150-151.
9. Gupta S, Hendricks S, Kenkel AM, Bhatia SC, Haffke EA (1996). Relapse in schizophrenia: is there a relationship to substance abuse? Schizophrenia Research 20, 153-156.
10. Hassan AN, De Luca V (2015). The effect of lifetime adversities on resistance to antipsychotic treatment in schizophrenia patients. Schizophrenia Research 161, 496-500.
11. Hollis C (2000). Adult outcomes of child-and adolescent-onset schizophrenia: diagnostic stability and predictive validity. American Journal of Psychiatry 157, 1652-1659.
12. Ikeda M, Yamanouchi Y, Kinoshita Y, Kitajima T, Yoshimura R, Hashimoto S, O'Donovan MC, Nakamura J, Ozaki N, Iwata N (2008). Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics 9, 1437-1443.
13. International Schizophrenia Consortium (2014). Biological insights from 108 schizophrenia-associated genetic loci. Nature 511, 421-427.
14. Kane J, Honigfeld G, Singer J, Meltzer H (1988). Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 45, 789-796.
15. Korn JM, Kuruvilla FG, McCarroll SA, Wysoker A, Nemesh J, Cawley S, Hubbell E, Veitch J, Collins PJ, DarvishiK, Lee C, NizzariMM, Gabriel SB, Purcell S, DalyMJ, Altshuler D (2008). Integrated genotype calling and association analysis of SNPs, common copy number polymorphisms and rareCNVs. Nature Genetics 40, 1253-1260.
16. Lai TL, Xing H, Zhang N (2008). Stochastic segmentation models for array-based comparative genomic hybridization data analysis. Biostatistics 9, 290-307.
17. Lee SH, Decandia TR, Ripke S, Yang J, Sullivan PF, Goddard ME, Keller MC, Visscher PM, Wray NR (2012). Estimating the proportion of variation in susceptibility to schizophrenia captured by common SNPs. Nature Genetics 44, 247-250.
18. Lencz T, Robinson DG, Xu K, Ekholm J, Sevy S, Gunduz-Bruce H, Woerner MG, Kane JM, Goldman D, Malhotra AK (2006). DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. American Journal of Psychiatry 163, 529-531.
19. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, KisslingW, Stapf MP, Lassig B, Salanti G, Davis JM (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. Lancet 382, 951-962.
20. Levinson DF, Duan J, Oh S, Wang K, Sanders AR, Shi J, Zhang N, Mowry BJ, Olincy A, Amin F, Cloninger CR, Silverman JM, Buccola NG, Byerley WF, Black DW, Kendler KS, Freedman R, Dudbridge F, Pe'er I, Hakonarson H, Bergen SE, Fanous AH, Holmans PA, Gejman PV (2011). Copy number variants in schizophrenia: confirmation of five previous findings and new evidence for 3q29 microdeletions and VIPR2 duplications. American Journal of Psychiatry 168, 302-316.
21. Lieberman J, Jody D, Geisler S, Alvir J, Loebel A, Szymanski S, Woerner M, Borenstein M (1993). Time course and biologic correlates of treatment response in first-episode schizophrenia. Archives of General Psychiatry 50, 369-376.
22. Malaspina D, Goetz RR, Yale S, Berman A, Friedman JH, Tremeau F, Printz D, Amador X, Johnson J, Brown A, Gorman JM (2000). Relation of familial schizophrenia to negative symptoms but not to the deficit syndrome. American Journal of Psychiatry 157, 994-1003.
23. Martin AK, Robinson G, Reutens D, Mowry B (2014a). Cannabis abuse and age at onset in schizophrenia patients with large, rare copy number variants. Schizophrenia Research 155, 21-25.
24. Martin AK, Robinson G, Reutens D, Mowry B (2014b). Cognitive and structural neuroimaging characteristics of schizophrenia patients with large, rare copy number deletions. Psychiatry Research 224, 311-318.
25. Martin AK, Robinson G, Reutens D, Mowry B (2014c). Copy number deletion burden is associated with cognitive, structural, and resting-state network differences in patients with schizophrenia. Behavioural Brain Research 272C, 324-334.
26. Martin AK, Robinson G, Reutens D, Mowry B (2015a). Clinical and parental age characteristics associated with rare copy number variants in patients with schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 168B, 374-382.
27. Martin AK, Robinson G, Reutens D, Mowry B (2015b). Common genetic risk variants are associated with positive symptoms and decision-making ability in patients with schizophrenia. Psychiatry Research 229, 606-608.
28. Maxwell ME (1992). Family Interview for Genetic Studies (FIGS): A Manual for FIGS. Clinical Neurogenetics Branch, Intramural Research Program, NIMH: Bethesda, MD.
29. McGlashan TH (1988). A selective review of recent North American long-term followup studies of schizophrenia. Schizophrenia Bulletin 14, 515-542.
30. Meltzer H, Kostacoglu A (2001). Treatment-Resistant Schizophrenia. Martin Dunitz: London.
31. Miller A, McEvoy J, Jeste D, Marder SR (2006). Treatment of Chronic Schizophrenia. American Psychiatric Publishing: Washington, DC.
32. Mowry BJ, Gratten J (2013). The emerging spectrum of allelic variation in schizophrenia: current evidence and strategies for the identification and functional characterization of common and rare variants. Molecular Psychiatry 18, 38-52.
33. Murray RM, Van Os J (1998). Predictors of outcome in schizophrenia. Journal of Clinical Psychopharmacology 18, 2S-4S.
34. Nielsen J, Nielsen RE, Correll CU (2012). Predictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish Register Study. Journal of Clinical Psychopharmacology 32, 678-683.
35. Nurnberger Jr JI, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy-Friedman J, Severe JB, Malaspina D, Reich T (1994). Diagnostic Interview for Genetic Studies. Rationale, unique features, and training. NIMH Genetics Initiative. Archives of General Psychiatry 51, 849-859; discussion 863-864.
36. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC (2007). PLINK: A tool set for whole-genome association and population-based linkage analyses. American Journal of Human Genetics 81, 559-575.
37. Rasmussen H, Ebdrup BH, Erritzoe D, Aggernaes B, Oranje B, Kalbitzer J, Pinborg LH, Baare WF, Svarer C, Lublin H, Knudsen GM, Glenthoj B (2011). Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine. Psychopharmacology 213, 583-592.
38. Reichert A, Kreiker S, Mehler-Wex C, Warnke A (2008). The psychopathological and psychosocial outcome of early-onset schizophrenia: preliminary data of a 13-year follow-up. Child and Adolescent Psychiatry and Mental Health 2, 6.
39. Revicki DA, Luce BR, Weschler JM, Brown RE, Adler MA (1990). Cost-effectiveness of clozapine fortreatment-resistant schizophrenic patients. Hospital and Community Psychiatry 41, 850-854.
40. Schennach R, Riedel M, Musil R, Moller HJ (2012). Treatment response in first-episode schizophrenia. Clinical Psychopharmacology and Neuroscience 10, 78-87.
41. Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014). Biological insights from 108 schizophrenia-associated genetic loci. Nature 511, 421-427.
42. Sullivan PF, Posthuma D (2015). Biological pathways and networks implicated in psychiatric disorders. Current Opinion in Behavioral Sciences 2, 58-68.
43. Wang K, Li M, Hadley D, Liu R, Glessner J, Grant SF, Hakonarson H, Bucan M (2007). PennCNV: An integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome Research 17, 1665-1674.
44. Wray NR, Lee SH, Mehta D, Vinkhuyzen AA, Dudbridge F, Middeldorp CM (2014). Research review: polygenic methods and their application to psychiatric traits. Journal of Child Psychology and Psychiatry and Allied Disciplines 55, 1068-1087.
45. Yeo RA, Gangestad SW, Liu J, Ehrlich S, Thoma RJ, Pommy J, Mayer AR, Schulz SC, Wassink TH, Morrow EM, Bustillo JR, Sponheim SR, Ho BC, Calhoun VD (2013). The impact of copy number deletions on general cognitive ability and ventricle size in patients with schizophrenia and healthy control subjects. Biological Psychiatry 73, 540-545.
46. Yeo RA, Gangestad SW, Walton E, Ehrlich S, Pommy J, Turner JA, Liu J, Mayer AR, Schulz SC, Ho BC, Bustillo JR, Wassink TH, Sponheim SR, Morrow EM, Calhoun VD (2014). Genetic influences on cognitive endophenotypes in schizophrenia. Schizophrenia Research 156, 71-75.
47. Zhang JP, Malhotra AK (2011). Pharmacogenetics and antipsychotics: Therapeutic efficacy and side effects prediction. Expert Opinion on Drug Metabolism and Toxicology 7, 9-37.